News

T cells prevent the disease from developing seriously after the first vaccination. However, only after the second vaccination dose do antibodies offer reliable protection against infection.

With beginning of 2022, Prof. Dr. Robert Thimme (A02) is a new member in the DFG Senate Committee on Collaborative Research Centers and thus a scientific member of the Grants Committee on Collaborative Research Centers.

Prof. Dr. Marco Prinz (C03) was appointed to the National Academy of Sciences in July 2021.

Dr. Sandra Ammann (B04) was awarded this year’s Walter-Hitzig Prize from the “Arbeitsgemeinschaft Pädiatrische Immunologie (API)” .

Prof. Dr. Stephan Ehl, spokesperson and principal investigator in the CRC 1160 (A01, A07), was elected as President of the German/Swiss/Austrian Working group for Pediatric Immunology (API) for a term of 2 years beginning in May 2021.

Dr. Maike Hofmann (A02) was awarded this year’s Adolf Kussmaul Prize from the Southwest German Society for Gastroenterology at the end of June. Hofmann recently showed that virus-specific CD8 + T cells have a molecular scar and are no longer fully functional, even after a successfully treated chronic hepatitis C virus infection. These findings are relevant for the development of new therapies.

Prof. Dr. Robert Zeiser is honored in the “Translational Research” section for his research that improves therapy after stem cell transplants. The award ceremony can be followed via livestream.

Veranstaltungsreihe Online-Fortbildungen zur Zell- und Gentherapie – Prof. Dr. Toni Cathomen (A07): “Neue Wege in der HIV-Gentherapie mittels Genom-Editierung” am 15.06.2021

Prof. Dr. Marco Prinz (C03) receives the Novo Nordisk Prize 2021, endowed with 672,000 euros. The award goes to his research on the immune system of the brain, the so-called microglia.

Prof. Dr. Stephan Ehl (A01) berichtet am 05. Mai 2021 um 18.30 Uhr unter anderem, wie klinische Beobachtungen an Einzelpatienten grundlegende Einblicke in Aufbau und Funktion des menschlichen Immunsystems geben können.

The “IMMediate – Immune-Mediated Diseases” program at the Medical Center – University of Freiburg is based in the fields of immunology, oncology and cell biology. It supports Advanced Clinician Scientists who examine immune-mediated diseases that affect e.g. the brain, heart, liver or intestine.

Prof. Dr. Robert Zeiser is honored in the “Translational Research” section for his research that improves therapy after stem cell transplants.

Prof. Dr. Toni Cathomen, principal investigator in the CRC 1160 (A07), was appointed President of the German Society for Gene Therapy (DG-GT e.V.) for a term of two years at the beginning of January 2021.

Prof. Dr. Olaf Groß, principal invetigator in the CRC 1160 (C02N), receives ERC proof of concept funding for his project IMMUNOSTIM.

Prof. Dr. Robert Thimme (A02) berichtet am 13. Januar 2021 um 18.30 Uhr unter anderem, wie Hepatitisforschung zur Bekämpfung der Corona-Pandemie beitragen kann.